Genetesis Accelerated Registry
Key facts
- Who runs it
- Genetesis Inc.
- Where
- Mason, United StatesSee the site
- Trial code
- Status
- Suspended
- People taking part
- 500 people, planned
- Started
- 27 Jan 2021
- Ended
- Jul 2024
- Type of study
- Observational
- Treatments tested
- CardioFlux
- Record updated
- 23 February 2023
- Why it stopped
- Resourcing
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- ≥ 18 years of age at the time of enrollment
Who cannot take part
- Patients with present with or have reasonable clinical suspicion of any acute coronary syndrome for which delayed intervention could increase the risk or magnitude of damaged myocardium
- < 18 years of age
- Patients unable to fit into device
- Non-ambulatory patients
- Patients with claustrophobia or unable to lie supine for 5 minutes
- Pregnant women
- Poor candidate for follow-up (e.g. no access to phone)
- Prisoners
- Patients with a language barrier/language difficulties
Where in United States
- Genetesis FacilityMason, United States
About the trial
What the trial wants to find out
Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood pressure, high cholesterol, family history of heart disease, and diabetes. The purpose of the Genetesis Accelerated Registry (GEAR) study is to understand the potential for magnetocardiography to be utilized as a diagnostic, screening or surveillance tool for heart disease in healthy and non-healthy volunteers. Magnetocardiography (MCG) is a diagnostic method that analyzes and records the magnetic fields of the heart for the detection of various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 500 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.
The group in the trial
- GEAR cohort
This is a noninvasive study that screens healthy and non-healthy volunteers for cardiovascular disease.
Treatment: CardioFlux
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 February 2023